APA (7th ed.) Citation

L, M., BN, R., F, E. C., L, F., T, T., G, A., . . . P, B. (2025). A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Frontiers in medicine, 12, 1548590. https://doi.org/10.3389/fmed.2025.1548590

Chicago Style (17th ed.) Citation

L, Masarova, et al. "A Multicenter Study to Assess Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft in Patients with Essential Thrombocythemia in the US and Canada: EXCEED-ET Trial." Frontiers in Medicine 12 (2025): 1548590. https://doi.org/10.3389/fmed.2025.1548590.

MLA (9th ed.) Citation

L, Masarova, et al. "A Multicenter Study to Assess Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft in Patients with Essential Thrombocythemia in the US and Canada: EXCEED-ET Trial." Frontiers in Medicine, vol. 12, 2025, p. 1548590, https://doi.org/10.3389/fmed.2025.1548590.